Can Women with Atypical Endometrial Hyperplasia and Infertility Become Pregnant?
Yes, women with atypical endometrial hyperplasia (AEH) and infertility can become pregnant through fertility-sparing treatment with progestins, though success rates are modest and require careful patient selection and monitoring. 1
Treatment Approach and Eligibility
Fertility-sparing therapy is appropriate only for highly selected patients who meet strict criteria:
- Diagnosis must be confirmed by specialist gynaecopathologist, preferably via D&C 1
- Pelvic MRI required to exclude myometrial invasion and adnexal involvement 1
- No metastatic disease present 1
- Patient must understand this is non-standard treatment and accept close follow-up 1
- Genetic counseling and testing should be performed 1
Recommended Treatment Regimens
First-line hormonal therapy options include: 1
- Medroxyprogesterone acetate (MPA): 400-600 mg/day orally 1
- Megestrol acetate (MA): 160-320 mg/day orally 1
- Levonorgestrel-releasing intrauterine device (LNG-IUD) with or without GnRH analogues 1
The addition of metformin to progestins may slightly increase complete response rates 2. LNG-IUD may reduce adverse events (particularly weight gain) compared to oral progestins while maintaining similar efficacy 2.
Expected Outcomes
Complete response rates and pregnancy outcomes:
- Approximately 75% of patients achieve complete response to conservative management 1
- Overall pregnancy rate: 56-63% depending on treatment regimen 3
- Live birth rate: approximately 27-28% overall 3, 1
- Among those achieving complete response and attempting pregnancy: 35% successfully conceive 1
- Recurrence rate after initial response: 30-40% 1
Critical caveat: Women with known primary infertility or severe polycystic ovary syndrome show inadequate pregnancy rates even after successful treatment 4. The underlying infertility must be addressed concurrently.
Monitoring Protocol
Mandatory surveillance schedule: 1
- Endometrial sampling (biopsy or D&C) every 3-6 months
- Assess response at 6 months with repeat D&C and imaging 1
- If complete response achieved, encourage immediate conception and refer to fertility clinic 1
- Consider maintenance treatment for responders who wish to delay pregnancy 1
When to Proceed to Surgery
Hysterectomy with bilateral salpingo-oophorectomy is recommended: 1
- After childbearing is complete
- If documented progression on biopsy
- If disease persists after 6-12 months of progestin therapy
- For non-responders at 6 months 1
Ovarian preservation may be considered based on age and genetic risk factors 1.
Assisted Reproductive Technology
For patients achieving complete response:
- Pregnancy is associated with reduced recurrence risk 1
- All assisted reproduction techniques can be utilized 5
- Live birth rate reaches 39% when ART is used 1
- In patients with endometrial hyperplasia undergoing IVF, the early-follicular long protocol is superior to midluteal long protocol (61.8% vs 43.5% clinical pregnancy rate) 6
Important Contraindications
Progestin therapy should not be used in patients with: 1
- Breast cancer
- Stroke or myocardial infarction history
- Pulmonary embolism or deep vein thrombosis
- Active smoking
Bottom Line
Women with AEH and infertility can achieve pregnancy through fertility-sparing treatment, but success requires meeting strict eligibility criteria, achieving complete response to hormonal therapy (which occurs in ~75% of cases), and often necessitates assisted reproductive technology 1, 3. The ultimate recurrence rate remains high at 30-40%, making definitive surgery mandatory after childbearing completion 1.